Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a biopharmaceutical company, is set to present new preclinical data on its TNX-801 vaccine candidate at the Vaccine Congress 2025 in Vienna. The presentation, scheduled for July 10, will be delivered by Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development at Tonix. TNX-801, a recombinant horsepox virus live vaccine, has demonstrated protective efficacy against mpox and other orthopoxviruses in animal models following a single dose. The vaccine platform is designed to elicit durable immune responses and has the potential to be adapted for other emerging viral threats.
The upcoming presentation will focus on the safety, immunogenicity, and efficacy findings from preclinical studies of TNX-801. Additionally, Tonix Pharmaceuticals plans to initiate clinical trials for the vaccine candidate, marking a significant step forward in the development of a new tool against mpox and related viruses. The company's commitment to addressing public health challenges is further evidenced by its state-of-the-art infectious disease research facility in Frederick, Maryland, and its GMP-capable manufacturing facility in Dartmouth, Maryland, which is prepared to produce TNX-801 in response to national or international emergencies.
Tonix Pharmaceuticals' broader portfolio includes therapies for pain management, CNS disorders, and immunology, with several product candidates in various stages of development. The company's focus on innovative solutions for pressing health issues underscores the importance of the TNX-801 vaccine data presentation at Vaccine Congress 2025, as it represents a potential advancement in the fight against mpox and other infectious diseases.
